L 161240

Drug Profile

L 161240

Latest Information Update: 15 Jun 2001

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antibacterials
  • Mechanism of Action Deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Gram-negative infections

Most Recent Events

  • 15 Jun 2001 No-Development-Reported for Gram-negative infections in USA (Parenteral)
  • 12 May 1997 New profile
  • 12 May 1997 Preclinical development for Gram-negative infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top